Allos

Many approved drugs, especially complex generics biosimilars, remain suboptimal due to poor tolerability, delivery or adherence. Reformulating them is costly, risky and uncertain, so manufacturers avoid reinvestment, leaving patients on outdated treatments despite clear opportunities to improve outcomes.

Allos applies Causal AI to medicinal chemistry to reformulate faster, using a lab-in-the-loop approach. It can also apply the same techniques to understand how formulation chemistry and patient biology interact, enabling smaller, faster, and more predictable clinical studies, reducing development risk and making drug improvement a repeatable, evidence-driven engineering process.

An AI-native company backed by OSE, Allos is focused on complex small-molecule drugs within a rapidly growing specialty generics market. Its interdisciplinary team combines AI, physics and drug development expertise to unlock stalled programs and improve existing medicines.